Loading the records…
Loading the records…
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH - CC
National Institutes of Health is planning to buy "Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)". This is an early notice: it is not taking bids yet. The work is in Bethesda, MD, USA. Responses are due Nov 11, 2026. In the last 2 years, similar work went to 3 companies, usually for about $137K per award. An award is expected between December 2026 and September 2027.
Put together from the facts on this page; the details and sources are below.
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Every notice posted under solicitation NOI-27-000056 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6505.
Single-winner award sizes (3): middle half $82K to $470K, median $137K; range $28K to $804K.
| Winner | Awards | Value | Last |
|---|---|---|---|
| VECTOR BIOMED INC. | 1 | $804K | Dec 2, 2024 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC · $PACB · $159.3M | 1 |
| $137K |
| Nov 19, 2024 |
| 10X GENOMICS, INC. · $TXG · $616.9M | 1 | $28K | Dec 20, 2024 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
One award's total value against one year of revenue; many awards are paid over several years.
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.